Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Prognostic Factors of Local Control, Overall Survival, and Toxicity

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Bibault, Jean Emmanuel ^a   Dewas, Sylvain ^a   Vautravers Dewas, Claire ^a   Hollebecque, Antoine ^b   Jarraya, Hajer ^c   Lacornerie, Thomas ^a   Lartigau, Eric ^a   Mirabel, Xavier ^a  

^a UNIV LILLE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Department of Radiology CLCC Oscar Lambret ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; SORAFENIB;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER CONTROL; CANCER PROGNOSIS; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CHILD TURCOTTE PUGH SCORE; CYBERKNIFE; FEMALE; FIDUCIAL MARKER; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PROTEIN BLOOD LEVEL; RADIATION INJURY; RADIATION RESPONSE; RADIOTHERAPY SOFTWARE; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT RESPONSE; ADVERSE EFFECTS; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RADIATION DOSE FRACTIONATION; RADIOSURGERY; TREATMENT OUTCOME; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOSURGERY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; ADULT; CARCINOMA, HEPATOCELLULAR; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; LIVER NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84885412598     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077472     Document Type: Article

References (30)

1. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, et al. (2006) The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 43: 1303-1310. doi:10.1002/hep.21176. PubMed: 16729298.
2. Villanueva A, Hernandez-Gea V, Llovet JM, (2013) Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat. Rev Gastroenterol Hepatol 10: 34-42. doi:10.1038/nrgastro.2012.199.
3. Lencioni R, Crocetti L, (2012) Local-regional treatment of hepatocellular carcinoma. Radiology 262: 43-58. doi:10.1148/radiol.11110144. PubMed: 22190656.
4. Lencioni R, (2012) Chemoembolization for hepatocellular carcinoma. Semin Oncol 39: 503-509. doi:10.1053/j.seminoncol.2012.05.004. PubMed: 22846867.
5. Xie B, Wang DH, Spechler SJ, (2012) Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci 57: 1122-1129. doi:10.1007/s10620-012-2136-1. PubMed: 22451120.
6. Feng M, Ben-Josef E, (2011) Radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol 21: 271-277. doi:10.1016/j.semradonc.2011.05.002. PubMed: 21939856.
7. Qian J, Feng G-S, Vogl T, (2003) Combined interventional therapies of hepatocellular carcinoma. World J Gastroenterol 9: 1885-1891. PubMed: 12970869.
8. Bruix J, Sherman M, (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022. doi:10.1002/hep.24199. PubMed: 21374666.
9. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma (2012). J Hepatol 56: 908-943. doi:10.1016/j.jhep.2011.12.001. PubMed: 22424438.
10. Comet B, Kramar A, Faivre-Pierret M, Dewas S, Coche-Dequeant B, et al. (2012) Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 84: 203-209. doi:10.1016/j.ijrobp.2011.11.054. PubMed: 22331006.
11. Dewas S, Bibault JE, Mirabel X, Nickers P, Castelain B, et al. (2011) Robotic image-guided reirradiation of lateral pelvic recurrences: preliminary results. Radiol Oncol 6: 77. doi:10.1186/1748-717X-6-77. PubMed: 21699690.
12. Blomgren H, Lax I, Näslund I, Svanström R, (1995) Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator: clinical experience of the first thirty-one patients. Acta Oncol 34: 861-870. doi:10.3109/02841869509127197. PubMed: 7576756.
13. Vautravers-Dewas C, Dewas S, Bonodeau F, Adenis A, Lacornerie T, et al. (2011) Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship? Int J Radiat Oncol Biol Phys 81: e39-e47. doi:10.1016/j.ijrobp.2010.12.047. PubMed: 21377292.
14. Klein J, Dawson LA, (2012) Hepatocellular Carcinoma Radiation Therapy: Review of Evidence and Future Opportunities. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2012.08.043.
15. Dewas S, Bibault J-E, Mirabel X, Fumagalli I, Kramar A, et al. (2012) Prognostic factors affecting local control of hepatic tumors treated by Stereotactic Body Radiation Therapy. Radiol Oncol 7: 166. doi:10.1186/1748-717X-7-166. PubMed: 23050794.
16. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference European Association for the Study of the Liver J Hepatol 35: 421-430.
17. Lencioni R, Llovet JM, (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30: 52-60. doi:10.1055/s-0030-1247132. PubMed: 20175033.
18. Common NCI, Terminology Criteria for Adverse Events (CTCAE) v.4 (n.d.). Available: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
19. Kang J-K, Kim M-S, Cho CK, Yang KM, Yoo HJ, et al. (2012) Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer. Available: pp. http://www.ncbi.nlm.nih.gov/pubmed/22570179. Accessed 25 September 2012 PubMed: 22570179.
20. O'Connor JK, Trotter J, Davis GL, Dempster J, Klintmalm GB, et al. (2012) Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl 18: 949-954. doi:10.1002/lt.23439. PubMed: 22467602.
21. Huang W-Y, Jen Y-M, Lee M-S, Chang L-P, Chen C-M, et al. (2012) Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 84: 355-361. doi:10.1016/j.ijrobp.2011.11.058. PubMed: 22342300.
22. Méndez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJM, et al. (2006) Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol 45: 831-837. doi:10.1080/02841860600897934. PubMed: 16982547.
23. Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, et al. (2008) Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 26: 657-664. doi:10.1200/JCO.2007.14.3529. PubMed: 18172187.
24. McGinn CJ, Ten Haken RK, Ensminger WD, Walker S, Wang S, et al. (1998) Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model. J Clin Oncol 16: 2246-2252. PubMed: 9626227.
25. Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, et al. (2010) Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 10: 475. doi:10.1186/1471-2407-10-475. PubMed: 20813065.
26. Seo YS, Kim M-S, Yoo SY, Cho CK, Choi CW, et al. (2010) Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 102: 209-214. doi:10.1002/jso.21593. PubMed: 20740576.
27. Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, et al. (2011) Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 81: e447-e453. doi:10.1016/j.ijrobp.2011.04.011. PubMed: 21645977.
28. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, et al. (2013) Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma. J Clin Oncol 31: 1631-1639. doi:10.1200/JCO.2012.44.1659. PubMed: 23547075.
29. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390. doi:10.1056/NEJMoa0708857. PubMed: 18650514.
30. Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34. doi:10.1016/S1470-2045(08)70285-7. PubMed: 19095497.